Cullinan's zipalertinib shows 30.2% intracranial response rate in Phase 2 lung cancer trial
Bitget2026/10/19 11:06- Cullinan Therapeutics and Taiho Oncology announced Phase 2 REZILIENT2 results showing zipalertinib activity against brain metastases in patients with mutation-defined lung cancer.
- Patients had non-small cell lung cancer harboring EGFR exon 20 insertions or other uncommon EGFR mutations, with active central nervous system metastases.
- Zipalertinib produced durable intracranial responses and was well tolerated, supporting continued evaluation in this difficult-to-treat population.
- Results will be presented October 26, 2026, at the European Society for Medical Oncology Congress in Madrid.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix
According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.
Chun purchased 7,186 ETH worth $11.74 million

